DE69232909D1 - Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe - Google Patents

Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe

Info

Publication number
DE69232909D1
DE69232909D1 DE69232909T DE69232909T DE69232909D1 DE 69232909 D1 DE69232909 D1 DE 69232909D1 DE 69232909 T DE69232909 T DE 69232909T DE 69232909 T DE69232909 T DE 69232909T DE 69232909 D1 DE69232909 D1 DE 69232909D1
Authority
DE
Germany
Prior art keywords
disease
symptomology
neurological diseases
symptoms
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232909T
Other languages
English (en)
Inventor
Howard K Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69232909D1 publication Critical patent/DE69232909D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
DE69232909T 1991-02-22 1992-02-21 Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe Expired - Lifetime DE69232909D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66056191A 1991-02-22 1991-02-22
PCT/US1992/001365 WO1992014456A1 (en) 1991-02-22 1992-02-21 Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology

Publications (1)

Publication Number Publication Date
DE69232909D1 true DE69232909D1 (de) 2003-03-06

Family

ID=24650025

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232909T Expired - Lifetime DE69232909D1 (de) 1991-02-22 1992-02-21 Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe

Country Status (7)

Country Link
EP (1) EP0572560B1 (de)
JP (1) JPH06502184A (de)
AT (1) ATE231723T1 (de)
AU (1) AU668682B2 (de)
CA (1) CA2104594C (de)
DE (1) DE69232909D1 (de)
WO (1) WO1992014456A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
ATE214608T1 (de) * 1992-06-30 2002-04-15 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP1060750B1 (de) * 1993-03-29 2005-12-07 Queen's University At Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
JP3583239B2 (ja) * 1996-01-25 2004-11-04 花王株式会社 皮膚外用剤
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
WO1998043649A2 (en) * 1997-03-28 1998-10-08 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
WO2000027376A2 (de) * 1998-10-26 2000-05-18 Michael Schedler Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2001247458A (ja) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd トラネキサム酸亜鉛化合物を含む糖尿病治療剤
PE20021046A1 (es) * 2000-09-30 2002-12-14 Gruenenthal Chemie Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
MXPA05013692A (es) * 2003-06-23 2006-03-13 Neurochem Int Ltd Metodos para tratar trastornos por acumulacion de proteina.
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
DE602006016990D1 (de) 2005-12-22 2010-10-28 Bellus Health Int Ltd Behandlung von diabetischer nephropathie
WO2009019534A2 (en) 2006-10-12 2009-02-12 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
EP2322163A1 (de) * 2009-11-03 2011-05-18 Pharnext Neue therapeutische Ansätze zur Behandlung von Alzheimer-Krankheit
TWI736635B (zh) * 2016-06-13 2021-08-21 心悅生醫股份有限公司 苯甲酸鋰之共晶及其用途
CA3027297A1 (en) * 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US20210270852A1 (en) * 2018-06-15 2021-09-02 The Regents Of The University Of California Methods of Detecting Neuroaxonal Dystrophy Disorders Associated with Vitamin E Deficiency and Uses Thereof
EP3982819A4 (de) * 2019-06-12 2023-06-14 Huntington Medical Research Institutes Verfahren zur beurteilung und behandlung von morbus alzheimer und anwendungen davon
EP4257139A3 (de) * 2022-04-07 2023-12-13 Mitos Therapeutics Inc. Zusammensetzung zur verbesserung, prävention oder behandlung von muskelerkrankungen mit verbindungen auf sulfonamidbasis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895107A (en) * 1970-04-15 1975-07-15 Morrison L M CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals
US4039388A (en) * 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
GB1551416A (en) * 1976-08-27 1979-08-30 Beecham Group Ltd Long chain dioxy hypolipidaemics
US4309534A (en) * 1979-02-15 1982-01-05 University Of Delaware Renatured chitosan and process of making same
US4665069A (en) * 1985-04-02 1987-05-12 Barnett Rosenberg Analgesic composition and method of relieving pain
US4638014A (en) * 1985-08-26 1987-01-20 Research Corporation Anticonvulsant method and formulations
US4595586A (en) * 1985-08-30 1986-06-17 Eli Lilly And Company Moisturizing lotion
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4889722A (en) * 1985-12-16 1989-12-26 Ethicon, Inc. Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
DK536987A (da) * 1987-10-14 1989-04-15 Ferring Farma Lab Anvendelse af 5-aminosalicylsyre (5-asa) til fremstilling af et farmaceutisk praeparat til anvendelse ved reperfusionsbehandling
EP0648489A1 (de) * 1988-08-12 1995-04-19 Fisons Corporation Arylalkylamide die nervenschützende Eigenschaften besitzen
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material

Also Published As

Publication number Publication date
EP0572560A1 (de) 1993-12-08
CA2104594C (en) 2004-05-11
CA2104594A1 (en) 1992-08-23
WO1992014456A1 (en) 1992-09-03
EP0572560A4 (de) 1995-04-26
JPH06502184A (ja) 1994-03-10
EP0572560B1 (de) 2003-01-29
AU668682B2 (en) 1996-05-16
ATE231723T1 (de) 2003-02-15
AU1561492A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
DE69232909D1 (de) Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe
JP6444548B2 (ja) スルホアルキルエーテルシクロデキストリン組成物
EP1372735B1 (de) Hydroxyalkylstärke-wirkstoff-konjugate
DE3026398C2 (de)
DE69826452T2 (de) Stellenspezifische proteinmodifizierung
Lindner et al. Clathrin-associated proteins of bovine brain coated vesicles. An analysis of their number and assembly-promoting activity.
JPH04501260A (ja) 分画化方法
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
DE69826684T2 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
EP0265865A2 (de) Blutersatzmittel
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
EP0346501B1 (de) Arzneimittelzubereitung zur behandlung des immunmangels
ATE215967T1 (de) Aus harn isolierte antikoagulierende verbindung
RU94044534A (ru) Амино-производные тиазола, способы их получения и содержащие их фармацевтические композиции
Carlsson et al. Preparation of bovine mercaptalbumin by means of covalent chromatography
EP1548004A1 (de) Niedermolekulare biologische derivate
EP1597271B1 (de) Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung
DE4221836A1 (de) Das biochemisch aufgereinigte Mistel-Lektin (ML-1) als therapeutisch anwendbarer Immunmodulator
CN1556711A (zh) 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
JPS60258120A (ja) 胸腺製品の製造方法
BEPPU et al. Interaction of malondialdehyde-modified bovine serum albumin and mouse peritoneal macrophages
CH622527A5 (de)
DE2539778A1 (de) N-acetyliertes orgotein
DE69734356T2 (de) Diclofenac zur behandlung von vasculopathien

Legal Events

Date Code Title Description
8332 No legal effect for de